Trial · NCT00722631
Anti-Inflammatory Effects of Pioglitazone
NCT00722631, Not applicable, Completed, Kurume University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Anti-Inflammatory Effects of Pioglitazone. Trials, record NCT00722631. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00722631
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Anti-Inflammatory Effects of Pioglitazone
- NCT number
- NCT00722631
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 70 participants, actual
- Lead sponsor
- Kurume University
- Conditions
- Impaired Glucose Tolerance, Type 2 Diabetes Mellitus, Atherosclerosis
- Interventions
- Pioglitazone, Glimepiride
- First posted
- 2008-07-25
- Last updated
- 2012-09-27
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Effect of treatment on the nominal change in FDG uptake of atherosclerotic plaque from baseline after 4 months of treatment as measured by FDG-PET/CT imaging. | Baseline and 4 months after treatment | |
| Secondary | Change from baseline in plasma glucose/insulin homeostatic parameters and circulating markers of atherosclerosis | Baseline and 4 months and 5 years after treatment | |
| Secondary | Change from baseline in visceral fat | Baseline and 4 months and 5 years after treatment | |
| Secondary | All cardiovascular events and all cause death for 5 years | Baseline and 4 months and 5 years after treatment |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers5
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00722631
GET https://conductscience.org/api/trials/v1/NCT00722631/registered